$1.08 Billion is the total value of FRAZIER MANAGEMENT LLC's 34 reported holdings in Q2 2021. The portfolio turnover from Q1 2021 to Q2 2021 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| PHAT | PHATHOM PHARMACEUTICALS INC | $197,258,000 | -9.9% | 5,827,415 | 0.0% | 18.19% | +3.6% | |
| PASG | PASSAGE BIO INC | $66,322,000 | -24.3% | 5,009,219 | 0.0% | 6.12% | -12.9% | |
| MIRM | MIRUM PHARMACEUTICALS INC | $61,672,000 | -12.8% | 3,566,912 | 0.0% | 5.69% | +0.3% | |
| PCVX | VAXCYTE INC | $51,988,000 | +14.0% | 2,309,554 | 0.0% | 4.79% | +31.0% | |
| TRILLIUM THERAPEUTICS INC | $30,275,000 | -9.4% | 3,123,107 | 0.0% | 2.79% | +4.2% | ||
| ANAB | ANAPTYSBIO INC | $23,329,000 | +20.3% | 899,700 | 0.0% | 2.15% | +38.3% | |
| ALPN | ALPINE IMMUNE SCIENCES INC | $23,143,000 | -15.1% | 2,571,450 | 0.0% | 2.13% | -2.4% | |
| STRO | SUTRO BIOPHARMA INC | $18,616,000 | -18.3% | 1,001,421 | 0.0% | 1.72% | -6.1% | |
| ISEE | IVERIC BIO INC | $16,056,000 | +2.1% | 2,544,500 | 0.0% | 1.48% | +17.4% | |
| FLACU | FRAZIER LIFESCIENCES ACQU COunit 12/09/2025 | $15,085,000 | -1.1% | 1,501,000 | 0.0% | 1.39% | +13.7% | |
| RGNX | REGENXBIO INC | $13,673,000 | +13.9% | 351,954 | 0.0% | 1.26% | +30.9% | |
| MTEM | MOLECULAR TEMPLATES INC | $10,745,000 | -38.0% | 1,374,047 | 0.0% | 0.99% | -28.8% | |
| GRTS | GRITSTONE BIO INC | $9,412,000 | -3.2% | 1,030,878 | 0.0% | 0.87% | +11.3% | |
| EPIX | ESSA PHARMA INC | $9,046,000 | -1.7% | 316,616 | 0.0% | 0.83% | +13.0% | |
| EPZM | EPIZYME INC | $6,144,000 | -4.6% | 739,369 | 0.0% | 0.57% | +9.7% | |
| SRRK | SCHOLAR ROCK HLDG CORP | $4,508,000 | -43.0% | 156,000 | 0.0% | 0.42% | -34.4% | |
| FRLN | FREELINE THERAPEUTICS HLDGSsponsored ads | $4,483,000 | -33.7% | 550,000 | 0.0% | 0.41% | -23.9% | |
| ALNA | ALLENA PHARMACEUTICALS | $4,329,000 | -6.5% | 3,330,373 | 0.0% | 0.40% | +7.5% | |
| BLU | BELLUS HEALTH INC NEW | $4,030,000 | -18.6% | 1,296,743 | 0.0% | 0.37% | -6.3% | |
| SRRA | SIERRA ONCOLOGY INC | $3,949,000 | +13.0% | 202,803 | 0.0% | 0.36% | +30.0% | |
| AVDL | AVADEL PHARMACEUTICALS PLCsponsored adr | $3,891,000 | -25.5% | 578,104 | 0.0% | 0.36% | -14.3% | |
| GRTX | GALERA THERAPEUTICS INC | $2,369,000 | +11.4% | 241,000 | 0.0% | 0.22% | +27.5% | |
| NABRIVA THERAPEUTICS PLC | $575,000 | -18.7% | 425,650 | 0.0% | 0.05% | -7.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2021-08-11
Signatures
The EDGAR filing(s) were signed by:
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| COLLEGIUM PHARMACEUTICAL INC | 21 | Q4 2020 | 37.0% |
| ANAPTYSBIO INC | 20 | Q4 2021 | 63.7% |
| CIDARA THERAPEUTICS INC | 20 | Q3 2020 | 17.2% |
| IOVANCE BIOTHERAPEUTICS INC | 19 | Q4 2021 | 13.7% |
| ALLENA PHARMACEUTICALS INC | 18 | Q1 2022 | 11.9% |
| ALPINE IMMUNE SCIENCES INC | 18 | Q4 2021 | 9.1% |
| APTINYX INC | 15 | Q4 2021 | 16.9% |
| KRYSTAL BIOTECH INC | 14 | Q4 2021 | 9.7% |
| GRITSTONE ONCOLOGY INC | 14 | Q4 2021 | 8.2% |
| SIERRA ONCOLOGY INC | 12 | Q4 2019 | 6.6% |
View FRAZIER MANAGEMENT LLC's complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 13F-HR | 2022-11-14 |
| 13F-HR | 2022-08-10 |
| 13F-HR | 2022-05-13 |
| 13F-HR | 2022-02-08 |
| 13F-HR | 2021-11-12 |
| 13F-HR | 2021-08-11 |
| 13F-HR | 2021-05-12 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-12 |
| 13F-HR | 2020-08-04 |
View FRAZIER MANAGEMENT LLC's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.